September 30, 2015 | Financial Wisdom
According to Zacks, “Amedisys reported impressive second-quarter financial results wherein the bottom and the top line exceeded the respective Zacks Consensus Estimate. In Home Health, the company continued to generate strong organic growth in Medicare and non-Medicare revenues. In Hospice, Amedisys successfully posted the company’s strongest quarterly same-store revenue growth in nearly three years. We are also upbeat about the company’s initiative to drive organic growth as well as its search for strategically fit merger and acquisition activities. The company’s declaration about its ongoing restructuring program expected to be cost neutral, also raises investors’ optimism.”
Several other brokerages have also commented on AMED. Piper Jaffray reaffirmed a hold rating and set a $41.00 target price (up from $30.00) on shares of Amedisys in a research note on Thursday, July 16th. Jefferies Group raised shares of Amedisys from a hold rating to a buy rating and increased their price objective for the company from $30.00 to $48.00 in a research report on Friday, June 19th. Mizuho assumed coverage on shares of Amedisys in a research report on Tuesday, June 30th. They issued a buy rating and a $45.00 target price on the stock. Wells Fargo started coverage on shares of Amedisys in a research note on Tuesday, September 1st. They set an outperform rating for the company. Finally, Deutsche Bank upgraded shares of Amedisys from a hold rating to a buy rating and raised their target price for the stock from $28.00 to $41.00 in a research note on Tuesday, June 9th. One analyst has rated the stock with a sell rating, six have given a hold rating and five have given a buy rating to the stock. The company presently has an average rating of Hold and a consensus target price of $34.78.